Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range
October 02 2018 - 4:01PM
Business Wire
The Company provides teleconference and
webcast details for Investor Meeting
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of
innovative treatments for aortic disorders, today announced that
its preliminary unaudited revenue for the third quarter ended
September 30, 2018 is expected to be in the range of $34.3 million
to $34.7 million.
Also, based on current business trends, the Company raised the
low end of its fiscal 2018 revenue guidance to $150 million. It now
anticipates 2018 revenue to be in the range of $150 million to $155
million, compared to the previous range of $145 million to $155
million.
Teleconference and Webcast Details
The Company will host a meeting for financial analysts and
investment professionals today at The London Hotel NYC, 151 W. 54th
St., New York, NY 10019. For those unable to attend in person, a
live teleconference and webcast of the presentations will begin at
4:15 p.m. ET.
To participate in the teleconference, dial 844-242-1698
(domestic) or 512-772-3064 (international) and refer to the
passcode 5966388.
A live webcast of the presentations will be available on the
“Investors” section of the Company’s website at www.endologix.com. Following the event, a replay
of the presentation and the associated materials will be available
on the same site.
A recording of the teleconference will also be available from
7:00 p.m. ET on Tuesday, October 2, 2018, until 11:59 p.m. ET on
Tuesday, October 9, 2018. To hear this recording, dial 855-859-2056
(domestic) or 404-537-3406 (international) and enter the passcode
5966388.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's focus is
endovascular stent grafts for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the
largest artery in the body, resulting in a balloon-like
enlargement. Once AAA develops, it continues to enlarge and, if
left untreated, becomes increasingly susceptible to rupture. The
overall patient mortality rate for ruptured AAA is approximately
80%, making it a leading cause of death in the United States. For
more information, visit www.endologix.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can generally be identified by the
use of words such as “anticipate,” “expect,” “could,” “may,”
“will,” “believe,” “estimate,” “forecast,” “goal,” “project,”
"continue," "outlook," “guidance,” "future,” and other words with
similar meanings. Forward-looking statements used in this press
release relate to, among other things, Endologix’s preliminary
revenue for the third quarter ended September 30, 2018 and
projected revenue for 2018. The forward-looking statements made in
this press release are subject to numerous risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. For
example, the Company’s preliminary revenue for the quarter ended
September 30, 2018 has been disclosed based on information
currently available to management, has not been subject to any
review procedures by our independent registered public accounting
firm, and are subject to adjustment based on final internal and
external review and audit. In addition, the Company’s ability to
achieve its projected revenue for 2018 will be impacted by numerous
factors, including: continued market acceptance of Endologix's
products; the success of Endologix’s restructuring and strategic
initiatives; the success of clinical trials relating to Endologix’s
products; Endologix’s product research and development efforts;
uncertainty in the process of obtaining and maintaining regulatory
approval for Endologix's products; Endologix’s ability to protect
its intellectual property rights and proprietary technologies; and
other economic, business, competitive and regulatory factors.
Please refer to Endologix's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2017, and its Quarterly Reports on
Form 10-Q for the quarters ended March 31, 2018 and
June 30, 2018, for more detailed information regarding these
risks and uncertainties, as well as other factors that may cause
actual results to differ materially from those expressed or implied
by the forward-looking statements. Readers are cautioned not to
place undue reliance on the forward-looking statements, which speak
only as of the date of this press release. Endologix undertakes no
obligation to update or review any forward- looking statements in
this press release to reflect new information, events or
circumstances after the date they are made, or to reflect the
occurrence of unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181002005943/en/
INVESTOR:Endologix, Inc.Vaseem Mahboob, CFO(949)
595-7200
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Sep 2023 to Sep 2024